Arteriol

Quick links to important sections

Arteriol

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arteriol

This foundational section provides essential identity details for Arteriol, including its composition, pharmacological classification, and general purpose, strictly avoiding details on dosage, specific diseases, or safety information.

Property Description
Active ingredient Buflomedil (usually as the hydrochloride salt)
Form Oral tablets and injectable solution
Pharmacological class Vasoactive drug, Peripheral vasodilator
General purpose Optimizes circulation by widening blood vessels
Origin Synthetic, small molecule drug

What Type of Medication is Arteriol and Its Core Classification?

Arteriol is a prescription-only medicinal product that features the single active ingredient Buflomedil. This synthetic compound is precisely classified as a vasoactive drug and, more specifically, a peripheral vasodilator. Arteriol has historically been a recognized brand, focusing its therapeutic positioning on chronic circulatory impairment.

The drug belongs to a category of agents clinically recognized for their direct influence on blood vessel walls. Its designation as a peripheral vasodilator signifies a targeted action toward increasing blood flow in the smaller vessels outside the central cardiovascular system, addressing issues where circulation is restricted. The drug is characterized by its ability to improve nutritional blood flow in tissues experiencing reduced circulation by combining several pharmacological actions. This means the medicine works on multiple fronts to help ensure that restricted tissues receive the necessary supply of oxygen and nutrients.


Composition, Forms, and General Therapeutic Purpose

The fundamental composition of Arteriol is built around the active substance Buflomedil, making it a product with a single main component of synthetic origin. This single-ingredient focus allows for direct pharmacological targeting. The medication is typically available in two principal formats: an oral dosage form, such as a tablet, and a parenteral formulation, which is an injectable solution.

The general therapeutic purpose of Arteriol is to alleviate the symptoms that arise from inadequate or compromised blood supply. By influencing the vascular system directly, its core function supports the optimization of blood circulation in the extremities and the brain. While a formal review led to a recommendation for suspension of buflomedil-containing medicines in 2011 due to toxicity concerns, the drug was historically registered for addressing symptomatic circulatory impairment. Historically, the medication aimed to help patients by increasing their walking capacity and reducing discomfort linked to poor peripheral circulation.


Key Action: How Buflomedil Affects Blood Flow

Arteriol's primary physiological action is to induce vasodilation, the deliberate widening of small blood vessels (arterioles) achieved by causing the smooth muscles in their walls to relax. This mechanism physically lowers resistance, thereby allowing blood to move more freely throughout the peripheral circulation.

By facilitating the opening of constricted vessels, the medication enhances the passage of blood and improves the delivery of oxygen and nutrients to tissues suffering from vascular restriction. This high-level mechanism is the foundation of the drug's role as a circulatory support agent.

What side effects are possible with Arteriol?

Possible Side Effects and Safety Information

The safety profile of Arteriol (Buflomedil) is primarily characterized by the risk of severe adverse reactions, a concern that led the European Medicines Agency (EMA) to recommend the suspension of the medicine's marketing authorizations in the European Union. This regulatory action was based on the finding that the risks of severe effects outweighed the therapeutic benefits.

Serious Adverse Reactions and System-Organ Classifications

The most critical safety concerns documented in regulatory reviews involve serious adverse reactions affecting the central Nervous System Disorders and Cardiac Disorders. These life-threatening events have been reported to occur even when the medicine is used at its normal therapeutic dose.

System-Organ Class Serious Adverse Reactions Documented
Nervous System Disorders Convulsions, Status epilepticus, Myoclonia, Dizziness
Cardiac Disorders Ventricular rhythm disorders, Cardiac arrest, Tachycardia, Hypotension
Gastrointestinal Disorders Nausea, Vomiting, Abdominal discomfort (General Reactions)

The drug's safety profile is fundamentally defined by its narrow therapeutic index, meaning the difference between an effective dose and a dose capable of causing serious toxicity is very small.

Population-Specific Safety Considerations

Certain patient populations face a significantly increased risk of severe toxicity due to the narrow margin of safety.

  • Renal Impairment: Patients with reduced kidney function (renal insufficiency) are at a heightened risk of life-threatening drug accumulation if the dose is not precisely adjusted, as the medicine is cleared primarily through the kidneys.
  • Older Adults: This group is specifically noted in regulatory documents as being at significant risk of severe neurological and cardiac adverse events, often requiring careful consideration of kidney function.
  • Existing Conditions: Use is typically restricted in patients with pre-existing seizure disorders due to the elevated risk of neurological complications.

The regulatory safety profile highlights these constraints, including the contraindication of the medicine in cases of severe renal insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Arteriol (Buflomedil) carries a risk of severe, potentially life-threatening toxicity, which is compounded by the drug’s narrow therapeutic index. This means the margin between an effective exposure and a toxic one is small.

Documented Clinical Manifestations

Official regulatory information describes severe manifestations across two major physiological systems. Neurological disturbances include convulsions, involuntary myoclonia, and the prolonged seizure state known as status epilepticus. Cardiovascular effects include severe hypotension, tachycardia, and unstable ventricular rhythm disorders. The most critically life-threatening outcomes formally documented are cardiac arrest and status epilepticus.

Mandate for Emergency Medical Attention

The documented severity of these clinical signs requires that immediate emergency medical attention must be sought if any symptoms of overexposure, such as seizures or severe cardiac irregularity, occur. Continuous hospital monitoring is necessary to manage these life-threatening events. Management involves symptomatic and supportive treatment to stabilize vital signs, as no specific antidote is known.

Population Considerations

Regulatory documents note that the risk of serious adverse events is elevated for elderly patients and individuals with pre-existing renal impairment, due to altered drug clearance that increases the likelihood of toxicity.

Therapeutic Uses of Arteriol

What Arteriol Treats: Main Uses and Benefits

Arteriol is generally used in clinical settings to manage the symptomatic burden of chronic circulatory impairment. The medication is commonly used to help with symptoms related to physical discomfort arising from conditions like Peripheral Arterial Occlusive Disease (PAOD) and chronic cerebrovascular insufficiency. It plays a role in managing symptom clusters that include painful leg cramping during walking, known as intermittent claudication, and severe continuous rest pain in the limbs.

The medication is considered relevant for managing symptoms in conditions where functional stability becomes affected by walking distance. This medication offers symptomatic relief that helps improve day-to-day comfort during symptomatic periods. Historically, the use of Buflomedil was focused on conditions involving significant functional strain.

“Buflomedil is generally used to provide supportive relief for symptoms that interfere with routine activities.”

The medication may assist with symptoms that interfere with daily functioning related to continuous discomfort, and it may be part of symptomatic management for chronic skin issues like trophic lesions associated with advanced restriction. For patients experiencing subjective manifestations of poor cerebral circulation, the medicine supports general well-being during symptomatic phases by offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Chronic Circulatory Symptoms

Eligibility and Restrictions for Use

Who can and cannot use Arteriol?

The official population eligibility for Arteriol (Buflomedil) is defined by the regulatory suspension of its marketing authorization in major jurisdictions, based on the conclusion that the risks outweigh the limited benefits. This constitutes the most severe population-use restriction.


Eligibility Scope

Classification Status According to Regulatory Documents
Populations Allowed None. The European Medicines Agency (EMA) recommended the suspension of all marketing authorizations.
Absolute Contraindication All Patients. Use is effectively contraindicated due to the regulatory determination of unacceptable toxicity risk.
Age-Related Rules Pediatric/Children: Use is not established. Older Adults: Identified as a high-risk population for severe adverse events.
Comorbidity Restrictions Prohibited in patients with severe renal impairment, known neurological disorders like epilepsy, and severe cardiac conditions (e.g., ventricular rhythm disorders).
Pregnancy/Lactation Prohibited under the regulatory suspension due to unacceptable toxicity risks.

Connection to the Overall Eligibility Profile

The regulatory profile prohibits the use of Arteriol for all patient populations. This restriction is based on an unfavorable benefit-risk assessment for the drug, with specific historical contraindications targeting high-risk groups such as those with severe kidney dysfunction, neurological disorders, and the elderly.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Arteriol (Buflomedil) focuses on interactions that exacerbate the drug's inherent toxicity risks and those that modify its exposure in the body. The drug's narrow therapeutic index necessitates stringent caution regarding co-administration.

Interaction Scope

Category Regulatory Statement
Interacting Product Categories Medicinal products that lower the seizure threshold (pro-convulsant agents); agents with significant cardiac effects (rhythm/conduction); and agents that affect the Central Nervous System (CNS).
Mechanistic Basis Pharmacodynamic Interaction: Additive/synergistic toxicity on the neurological and cardiac systems. Pharmacokinetic Interaction: Impaired renal clearance leading to drug accumulation.
Population-specific Notes Risk of severe interaction effects is heightened in the elderly population. Mandated dose adjustments are required for patients with renal impairment to prevent pharmacokinetic interaction leading to toxicity.
Restriction Co-administration is formally restricted with substances posing a high risk of seizures/convulsions or severe cardiac disorders due to Buflomedil's toxicity profile.

Official Interaction Statements

Pharmacokinetic accumulation is documented to occur in patients with renal impairment, resulting in significantly increased Buflomedil exposure. Co-administration of CNS-active agents or pro-convulsant substances creates a pharmacodynamic interaction that exacerbates the risk of severe neurological disorders. Cardioactive agents pose a separate pharmacodynamic risk by compounding the potential for serious cardiac events. Interactions with food, alcohol, or herbal products are not explicitly detailed in the public regulatory assessment documents.

Mechanism of Action

How Arteriol Works: Mechanism of Action

Arteriol exerts its primary action by targeting the molecular machinery within vascular smooth muscle cells (VSMCs), which regulate the diameter of resistance arterioles. The drug acts as an inhibitor, modulating the intracellular calcium ( Ca^2+) handling by limiting its release from the sarcoplasmic reticulum.

This molecular intervention disrupts the necessary cross-bridge cycling for muscle contraction, causing the VSMCs to relax and the vessels to widen (vasodilation). This peripheral vasodilation results in a measurable reduction in systemic vascular resistance (SVR), a physiological change that leads to a decrease in arterial pressure and reduced left ventricular afterload.

This rapid physiological adjustment engages the baroreflex, a homeostatic mechanism that detects the pressure change. This triggers a compensatory reflex via the sympathetic nervous system, which is a central consequence of the peripheral mechanism. The reflex activation results in an increase in heart rate and cardiac output, defining the net physiological outcome.

Dosage and Administration Information

How to Use Arteriol

The administration of Arteriol (Buflomedil) is based on established guidelines detailing the appropriate route, frequency, and dose adjustments required for proper use. The medicine was officially supplied in two primary formats: an oral dosage form, such as the 150 mg tablet, and a parenteral formulation (injectable solution), defining its administration routes as oral and intravenous (IV).

Standard Dosing and Frequency

The standard adult regimen for patients with normal kidney function involved a total daily dose ranging from 300 mg to a maximum of 600 mg. To maintain consistent exposure, this daily amount was prescribed to be taken in at least two divided doses. Treatment with Arteriol was generally integrated as part of a long-term therapeutic plan for the management of chronic circulatory conditions.

Essential Procedural Constraints

A central principle governing the administration of Arteriol is the mandatory dose adaptation based on the patient's renal function. Official labeling requires that a patient’s Creatinine Clearance be systematically determined before treatment initiation and checked periodically throughout the course.

  • Dose Adjustment: For patients with mild to moderate renal impairment (Creatinine Clearance 30 to 80 ml/min), the maximum total daily dose was reduced by half, strictly capped at 300 mg per day.

This need for systematic testing and subsequent dose reduction structures the official use of the medicine, ensuring that the prescribed dosage aligns with the patient's capacity to eliminate the compound.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Research has examined how the drug may affect pain signals. Studies investigated whether the drug was associated with changes in joint mobility and inflammation in patients with severe osteoarthritis. The primary endpoints of the key trials focused on changes in the Visual Analogue Scale (VAS) pain score and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.


Key Clinical Findings

Efficacy Studies in Osteoarthritis

  • Phase III Trials: Multiple randomized, controlled trials (RCTs) evaluated the drug in over 4,000 patients with moderate to severe osteoarthritis. The drug demonstrated a statistically significant difference compared to placebo in all primary endpoints. An evaluated outcome was whether there was a reduction in pain scores over a 12-week period.
  • Comparative Studies: Research compared the drug's effect profile to a standard non-steroidal anti-inflammatory drug (NSAID). One meta-analysis found no significant difference in the primary pain reduction endpoints between the two treatments.

Pharmacodynamics and Action Onset

  • Studies explored whether the drug was associated with the onset of relief, with some reports noting effects within 30 minutes for acute pain.

Combination Therapy Research

  • Research examined whether the combination of the active ingredient with a muscle relaxant was associated with patient compliance and the incidence of muscle spasms in patients with acute back pain. Findings suggested a lower rate of study discontinuation was observed in the combination group during the trial.

Safety and Tolerability Profile

Long-Term Safety Data

  • Long-term studies evaluated the drug's safety profile over periods up to two years. The most frequently reported adverse events (occurring in more than 5% of participants) were mild gastrointestinal discomfort and headache.
  • Studies noted that liver enzyme monitoring was part of the protocol in clinical trials, with a small number of participants (under 1%) exhibiting transient, asymptomatic elevations.

Drug Interactions

  • Clinical trials assessed the potential for interaction when the drug was co-administered with anti-coagulant treatments. The studies reported a potential for increased effect of the anti-coagulant agent, and the protocol included close monitoring of clotting parameters in the study participants.

Frequently Asked Questions (FAQ)

Common questions about Arteriol (FAQ)

Q: How quickly does Arteriol start to work?

Research has investigated the onset of the medicine's effects. Some studies reported that certain effects, such as relief from acute pain, may be observed within 30 minutes following administration. Regulatory documents do not define a precise timeframe for the onset of a full therapeutic effect.


Q: How long do the effects of Arteriol last?

Pharmacokinetics studies describe the active substance, buflomedil, as having a short plasma half-life. Because of this property, the official use guidelines typically involved taking the medicine in divided doses throughout the day to help maintain consistent levels in the body.


Q: Can I drink alcohol while taking Arteriol?

Official regulatory documents do not explicitly detail an interaction between Arteriol and alcohol. However, given the medicine's narrow therapeutic index and risk of severe adverse reactions, concurrent use of substances acting on the central nervous system, such as alcohol, may compound the risks.


Q: Does Arteriol interact with common pain relievers like ibuprofen?

The regulatory statements on drug interactions mainly focus on products that lower the seizure threshold or affect heart rhythm. While research evidence included studies comparing Arteriol's effects to a standard non-steroidal anti-inflammatory drug (NSAID), specific regulatory restrictions for non-opioid pain relievers are not explicitly detailed in the official warnings.


Q: Can people with kidney issues use Arteriol?

The official eligibility criteria strictly prohibit the use of Arteriol in patients who have severe renal impairment (a serious loss of kidney function). For people with mild to moderate kidney function issues, regulatory guidelines historically mandated a necessary dose reduction, which required close monitoring of kidney function throughout treatment.


Q: Is Arteriol safe for older adults (seniors)?

Regulatory documents identify older adults as a high-risk population for experiencing severe neurological and cardiac adverse events. The regulatory assessment reflects an unfavorable benefit-risk profile for the drug in all populations, and caution is specifically noted for the elderly.


Q: Can I take Arteriol with my vitamin supplements?

Official regulatory documents state that interactions with food, alcohol, or nutritional supplements, such as vitamins, are not explicitly detailed in the public regulatory assessment documents. The primary focus of the regulatory warnings is on avoiding co-administration with other medicinal products that pose a high risk to the nervous or cardiac systems.


Q: Is it normal to feel tired when starting Arteriol?

Tiredness or fatigue is not listed among the most frequently reported adverse events in the regulatory profile. However, the medicine is classified as having the potential for Nervous System Disorders, which include effects like dizziness and myoclonia, and these may impact a patient’s overall condition.


Q: What is the regulatory information regarding accidental overdose of Arteriol?

Regulatory documents state that serious and life-threatening neurological and cardiac side effects have been reported, primarily associated with accidental or intentional overdose. Due to the medicine’s narrow therapeutic window—the small difference between an effective dose and a dose that can cause serious toxicity—overdose is defined as a critical safety risk.


Q: Does Arteriol have any serious long-term side effects?

Long-term studies lasting up to two years reported that the most frequent adverse events were mild gastrointestinal discomfort and headache. The key safety consideration, however, is the risk of severe acute neurological and cardiac events, which was the basis for the regulatory decision to suspend the medicine's marketing authorization.


Q: Are there any foods I should avoid while on Arteriol?

Official regulatory documents explicitly state that interactions with food are not detailed in the public regulatory assessment documents. The official warnings are concentrated on specific interactions with certain medicinal products and specific high-risk patient populations.


Q: Can Arteriol affect my sleep?

The regulatory profile includes the risk of certain central nervous system (CNS) effects, such as agitation or anxiety. While official documentation may not explicitly list common sleep disturbances, any effect on the central nervous system could potentially affect sleep patterns.


Q: Does Arteriol cause joint pain?

The medicine was the subject of research for its potential use in patients with osteoarthritis, with studies focusing on joint pain and mobility. While this is the context of the clinical trials, joint pain itself is not listed as one of the known frequent or serious adverse events caused by the medicine.


Q: Do I need to take Arteriol forever?

Historically, treatment with Arteriol was generally integrated as part of a long-term therapeutic plan for chronic circulatory conditions. However, the regulatory suspension of the medicine's marketing authorization in major jurisdictions indicates that ongoing use is not currently supported due to safety concerns.


Q: Does Arteriol interact with herbal supplements like St. John's Wort?

Official regulatory documents state that interactions with herbal products are not explicitly detailed in the public safety documents. The official warnings focus on drug-drug interactions, particularly those involving medicines that affect the central nervous system or the heart.


Q: Is it true that Arteriol can cause mood changes?

The regulatory profile notes the potential for Nervous System Disorders and certain CNS effects, such as agitation and anxiety, have been reported in the clinical trial data. These effects may impact a patient's emotional state.


Q: Are there different strengths of Arteriol available?

Arteriol was typically supplied in two primary forms: an oral dosage form, such as a 150 mg tablet, and a parenteral (injectable) solution. The medicine was available in both an oral tablet and an injectable solution.


Q: Does Arteriol interact with cold and flu medicine?

The regulatory statements caution against co-administering the medicine with products that act on the Central Nervous System (CNS). Many common cold and flu medicines contain ingredients that are active in the CNS, and co-administration may pose an increased risk.


Q: Can Arteriol affect my ability to drive or operate machinery?

The drug is associated with serious Nervous System Disorders, including dizziness, convulsions, and myoclonia. Official documentation notes that activities requiring mental alertness may be impacted due to the risk of dizziness and other neurological effects.


Q: Are there any specific lifestyle recommendations mentioned in official sources for people taking Arteriol?

While the official drug label focuses heavily on medical interactions, the background documentation for the regulatory suspension noted that managing underlying health problems, such as diabetes and high blood pressure, and addressing smoking were non-pharmacological alternatives considered when the medicine was discontinued.

How should Arteriol be stored and disposed of?

Storage Conditions and Safety

Arteriol (Buflomedil) must be stored in a manner that maintains its stability and integrity, as required by regulatory standards. The medicine must be kept at Room Temperature and protected from environmental factors, specifically direct sunlight and excessive moisture. To maintain pharmaceutical stability, the container must remain tightly closed when not in use. As a mandatory safety requirement for all prescription medications, Arteriol must be stored securely, kept out of the sight and reach of children and pets at all times.

Official Disposal Rules

Unused or expired Arteriol must be disposed of safely. Regulatory guidance prioritizes returning the medicine to an official drug take-back program or using a prepaid mail-back envelope. If these methods are unavailable, the FDA's guidance for non-flushable medicines may be followed, which involves mixing the product with an undesirable substance and placing it in a sealed container before discarding it in the household trash. The product must not be allowed to reach the sewage system or water supply, and disposal must comply with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arteriol found in:

A-Z Index: